For the treatment of acute DVT with or without PE

? For patients who can be treated at home for acute DVT without PE, in conjunction with warfarin sodium therapy
Dosage: 1 mg/kg q12h SC; initiate warfarin sodium therapy when appropriate (usually within 72 hours of Lovenox administration)
Duration: Continue Lovenox for a minimum of 5 days and until a therapeutic oral anticoagulant effect has been achieved (INR 2.0-3.0). Up to 17 days of Lovenox administration has been well tolerated in clinical trails. Average duration: 7 days.

? For hospitalized patients with acute DVT with or without PE, in conjunction with warfarin sodium therapy
Dosage: 1.5 mg/kg qd SC at the same time every day OR 1 mg/kg q12h SC; initiate warfarin sodium therapy when appropriate (usually within 72 hours of Lovenox administration)
Duration: Continue Lovenox for a minimum of 5 days and until a therapeutic oral anticoagulant effect has been achieved (INR 2.0-3.0). Up to 17 days of Lovenox administration has been well tolerated in clinical trails. Average duration: 7 days.

For unstable angina and non-Q-wave MI

? For the prevention of ischemic complications of unstable angina and non-Q-wave myocardial infarction when concurrently administered with aspirin
 Dosage: 1 mg/kg q12h SC with oral aspirin therapy (100 to 325 mg once daily)
 Duration: Minimum 2 days; usual duration of therapy: 2 to 8 days
 

For prevention of deep vein thrombosis which may lead to pulmonary embolism

? In patients undergoing hip-replacement surgery
Dosage: 30 mg q12h SC; initiate 12 to 24 hours postop, provided hemostasis has been established at the wound site OR 40 mg qd SC; initiate 12(+/-3) hours preop.
Duration of prophylaxis: Up to 14 days of administration has been well tolerated in clinical trials. Average duration: 7 to 10 days.

? For extended prophylaxis in hip replacement
 Dosage: 40 mg qd SC: following initial phase of thromboprophylaxis (30 mg q12h or 40 mg qd)
 Duration of prophylaxis: 3 weeks postdischarge

? In patients undergoing knee-replacement surgery
Dosage: 30 mg q12h SC; initiate 12 to 24 hours postop, provided hemostasis has been established at the wound site
Duration of prophylaxis: Up to 14 days of administration has been well tolerated in clinical trials. Average duration: 7 to 10 days.

? In patients undergoing abdominal surgery who are at risk for thromboembolic complications
 Dosage: 40 mg qd SC; initiate 2 hours preop
Duration of prophylaxis: Up to 12 days of administration has been well tolerated in clinical trials. Average duration: 7 to 10 days

Return to The Intern in the Middle of the Night Home Page

Return to LSUHSC-S Family Medicine Home Page

Return to the LSUHSC-S Home Page.